Literature DB >> 35469044

NADPH oxidase 4 contributes to TRPV4-mediated endothelium-dependent vasodilation in human arterioles by regulating protein phosphorylation of TRPV4 channels.

Yangjing Xie1,2,3,4, Yoshinori Nishijima3, Natalya S Zinkevich3,5, Ankush Korishettar3,6, Juan Fang7,8, Angela J Mathison9, Michael T Zimmermann9, David A Wilcox7,8, David D Gutterman3,6, Yuxian Shen10,11, David X Zhang12,13.   

Abstract

Impaired endothelium-dependent vasodilation has been suggested to be a key component of coronary microvascular dysfunction (CMD). A better understanding of endothelial pathways involved in vasodilation in human arterioles may provide new insight into the mechanisms of CMD. The goal of this study is to investigate the role of TRPV4, NOX4, and their interaction in human arterioles and examine the underlying mechanisms. Arterioles were freshly isolated from adipose and heart tissues obtained from 71 patients without coronary artery disease, and vascular reactivity was studied by videomicroscopy. In human adipose arterioles (HAA), ACh-induced dilation was significantly reduced by TRPV4 inhibitor HC067047 and by NOX 1/4 inhibitor GKT137831, but GKT137831 did not further affect the dilation in the presence of TRPV4 inhibitors. GKT137831 also inhibited TRPV4 agonist GSK1016790A-induced dilation in HAA and human coronary arterioles (HCA). NOX4 transcripts and proteins were detected in endothelial cells of HAA and HCA. Using fura-2 imaging, GKT137831 significantly reduced GSK1016790A-induced Ca2+ influx in the primary culture of endothelial cells and TRPV4-WT-overexpressing human coronary artery endothelial cells (HCAEC). However, GKT137831 did not affect TRPV4-mediated Ca2+ influx in non-phosphorylatable TRPV4-S823A/S824A-overexpressing HCAEC. In addition, treatment of HCAEC with GKT137831 decreased the phosphorylation level of Ser824 in TRPV4. Finally, proximity ligation assay (PLA) revealed co-localization of NOX4 and TRPV4 proteins. In conclusion, both TRPV4 and NOX4 contribute to ACh-induced dilation in human arterioles from patients without coronary artery disease. NOX4 increases TRPV4 phosphorylation in endothelial cells, which in turn enhances TRPV4-mediated Ca2+ entry and subsequent endothelium-dependent dilation in human arterioles.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Coronary artery disease; Human arterioles; NADPH oxidase; Transient receptor potential vanilloid; Vasodilation

Mesh:

Substances:

Year:  2022        PMID: 35469044      PMCID: PMC9119129          DOI: 10.1007/s00395-022-00932-9

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   12.416


  71 in total

1.  Potentiation of TRPV4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity.

Authors:  Nicolas Cenac; Christophe Altier; Jean-Paul Motta; Emilie d'Aldebert; Sophie Galeano; Gerald W Zamponi; Nathalie Vergnolle
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

2.  Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.

Authors:  Tomonori Aoyama; Yong-Han Paik; Sumio Watanabe; Benoît Laleu; Francesca Gaggini; Laetitia Fioraso-Cartier; Sophie Molango; Freddy Heitz; Cédric Merlot; Cédric Szyndralewiez; Patrick Page; David A Brenner
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

3.  TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation.

Authors:  Ravi K Adapala; Anantha K Kanugula; Sailaja Paruchuri; William M Chilian; Charles K Thodeti
Journal:  Basic Res Cardiol       Date:  2020-01-10       Impact factor: 17.165

4.  Transient receptor potential vanilloid 4 (TRPV4) activation by arachidonic acid requires protein kinase A-mediated phosphorylation.

Authors:  Sheng Cao; Andriy Anishkin; Natalya S Zinkevich; Yoshinori Nishijima; Ankush Korishettar; Zhihao Wang; Juan Fang; David A Wilcox; David X Zhang
Journal:  J Biol Chem       Date:  2018-02-08       Impact factor: 5.157

5.  NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation.

Authors:  Siobhan M Craige; Kai Chen; Yongmei Pei; Chunying Li; Xiaoyun Huang; Christine Chen; Rei Shibata; Kaori Sato; Kenneth Walsh; John F Keaney
Journal:  Circulation       Date:  2011-07-25       Impact factor: 29.690

6.  Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries.

Authors:  N H Buus; U Simonsen; H K Pilegaard; M J Mulvany
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 7.  The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.

Authors:  Hua Cai; Kathy K Griendling; David G Harrison
Journal:  Trends Pharmacol Sci       Date:  2003-09       Impact factor: 14.819

Review 8.  Physiological Consequences of Coronary Arteriolar Dysfunction and Its Influence on Cardiovascular Disease.

Authors:  Hassan Allaqaband; David D Gutterman; Andrew O Kadlec
Journal:  Physiology (Bethesda)       Date:  2018-09-01

Review 9.  Coronary microvascular dysfunction.

Authors:  Paolo G Camici; Filippo Crea
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

10.  Reactive oxygen species facilitate the EDH response in arterioles by potentiating intracellular endothelial Ca(2+) release.

Authors:  James Chidgey; Paul A Fraser; Philip I Aaronson
Journal:  Free Radic Biol Med       Date:  2016-06-16       Impact factor: 7.376

View more
  1 in total

Review 1.  Inhibiting NADPH Oxidases to Target Vascular and Other Pathologies: An Update on Recent Experimental and Clinical Studies.

Authors:  Anthony L Sylvester; David X Zhang; Sophia Ran; Natalya S Zinkevich
Journal:  Biomolecules       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.